ChemoCentryx (NASDAQ:CCXI) Shares Gap Up to $18.20

ChemoCentryx, Inc. (NASDAQ:CCXI) shares gapped up prior to trading on Monday . The stock had previously closed at $18.20, but opened at $18.99. ChemoCentryx shares last traded at $18.94, with a volume of 11,309 shares traded.

A number of equities analysts have issued reports on the company. Canaccord Genuity lowered their target price on ChemoCentryx from $79.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, August 11th. Stifel Nicolaus upgraded ChemoCentryx from a “hold” rating to a “buy” rating and upped their target price for the company from $26.00 to $31.00 in a research report on Tuesday, July 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, ChemoCentryx presently has a consensus rating of “Buy” and an average target price of $37.88.

The firm has a fifty day simple moving average of $15.40 and a 200-day simple moving average of $23.81. The firm has a market cap of $1.31 billion, a P/E ratio of -10.28 and a beta of 1.46. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.73 and a quick ratio of 5.73.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings results on Sunday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.01). The firm had revenue of $1.81 million during the quarter, compared to the consensus estimate of $4.85 million. ChemoCentryx had a negative return on equity of 33.17% and a negative net margin of 568.54%. The firm’s revenue was down 96.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.29 EPS. On average, equities analysts predict that ChemoCentryx, Inc. will post -1.88 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of ChemoCentryx in the second quarter valued at approximately $622,000. Parametric Portfolio Associates LLC lifted its holdings in shares of ChemoCentryx by 120.5% in the second quarter. Parametric Portfolio Associates LLC now owns 144,988 shares of the biopharmaceutical company’s stock valued at $1,941,000 after purchasing an additional 79,245 shares in the last quarter. Integral Health Asset Management LLC lifted its holdings in shares of ChemoCentryx by 12.9% in the second quarter. Integral Health Asset Management LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $2,343,000 after purchasing an additional 20,000 shares in the last quarter. Morgan Stanley lifted its holdings in shares of ChemoCentryx by 10.1% in the second quarter. Morgan Stanley now owns 388,061 shares of the biopharmaceutical company’s stock valued at $5,197,000 after purchasing an additional 35,607 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of ChemoCentryx in the second quarter valued at approximately $254,000. Institutional investors and hedge funds own 63.20% of the company’s stock.

ChemoCentryx Company Profile (NASDAQ:CCXI)

ChemoCentryx, Inc is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.

Featured Story: Basic Economics creates winners and losers

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.